stockrow
Saturday 7 November 2026
Export IPSC’s income statement to Excel — free account
Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024.
- Revenue
- +12,667.7%
- EPS
- +55.3%
- Free cash flow
- +26.7%
Quarter to June 2026, against a year earlier
1.69
0.18
+11.92%
Follow IPSC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 5 | 2 | 7 | 109 | 115 | +175.9% | — | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (245) | (54) | (96) | (131) | (135) | (125) | (10) | (110) | (41.7%) | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (2,516.66) | (6,030.96) | (1,893.70) | (8.84) | 0.00 | (8.8) pt | ||||||
| Net income | — | 0 | — | (245) | (54) | (96) | (131) | (137) | (127) | (10) | (110) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.09 | 0.04 | 0.08 | 1.26 | 0.00 | n/m | |||||
| Earnings | — | — | — | (4.46) | (7.16) | (2.96) | (2.27) | (2.30) | (1.61) | (0.14) | (0.93) | (43.8%) | ||||||
| Cash flow | — | — | — | (0.29) | (5.52) | (2.75) | 0.24 | (1.49) | (1.40) | (1.20) | (0.42) | +26.4% | ||||||
| Capex | — | — | — | 0.00 | (1.31) | (1.39) | (0.53) | (0.23) | 0.00 | (0.01) | (0.01) | n/m | ||||||
| Free cash flow | — | — | — | (0.29) | (6.83) | (4.14) | (0.29) | (1.72) | (1.40) | (1.21) | (0.43) | +26.5% | ||||||
| Book value | — | — | — | 2.88 | 9.80 | 12.23 | 5.24 | 3.11 | 2.05 | 1.84 | 1.13 | (7.2%) | ||||||
| Shares, m | — | — | — | 55 | 7 | 32 | 58 | 59 | 79 | 87 | 143 | +7.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 55.21 | 96.60 | 12.06 | 0.75 | 3.03 | 41.2 | ||||||
| P/B | — | — | — | — | — | — | 0.95 | 1.17 | 0.49 | 0.54 | 1.50 | 0.8 | ||||||
| EV/Sales | — | — | — | — | — | — | (3.20) | 19.60 | (16.66) | (0.27) | 1.99 | (0.1) | ||||||
| EV/FCF | — | — | — | — | — | — | 1.00 | (0.43) | 1.00 | 0.30 | (2.59) | 0.5 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (16) | (41) | (89) | 14 | (88) | (110) | (104) | (87) | +36.3% | |||||
| Capex | — | — | — | (2) | (10) | (45) | (31) | (14) | 0 | (1) | (1) | (16.3%) | ||||||
| Free cash flow | — | — | — | (16) | (51) | (134) | (17) | (102) | (110) | (105) | (88) | +36.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 81 | 67 | 212 | 290 | 159 | 64 | 101 | 110 | +3.6% | |||||
| Net debt | — | — | — | (82) | (66) | (210) | (304) | (172) | (189) | (117) | (120) | +6.2% | ||||||
| Shareholders’ equity | — | — | — | 158 | 73 | 396 | 303 | 185 | 161 | 159 | 232 | +0.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (304.26) | (40.03) | (35.22) | (28.34) | (32.26) | (35.46) | (3.32) | (38.41) | +300.9 pt | |||||
| ROIC | — | — | — | 0.00 | (450.83) | (31.83) | 0.00 | (723.93) | 0.00 | (25.79) | (64.92) | (25.8) pt | ||||||
| ROE | — | — | — | (186.03) | 83.53 | (66.13) | (37.46) | (56.07) | (73.14) | (5.98) | (49.65) | +180.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 107 | 188 | 184 | 165 | 150 | 78 | — | (6.1%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.03 | 0.01 | 0.04 | 1.40 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 25 Oct 2026
Century Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics, Inc. | $280.8M | — (loss-making) | — (loss-making) | +27,018.64% (above 0%: growing) | n/m | −13.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| OCGN Ocugen, Inc. | $276.9M | — (loss-making) | — (loss-making) | +11.36% (above 0%: growing) | n/m | −22.15% (below 0%: shrinking) | 100.00% | (909.94%) | Compare |
| DTIL Precision BioSciences, Inc. | $275.7M | — (loss-making) | — (loss-making) | +37,272.41% (above 0%: growing) | n/m | −0.52% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NAUT Nautilus Biotechnology, Inc. | $273.9M | — (loss-making) | — | — | n/m | −28.59% (below 0%: shrinking) | 89.74% | (7,152.56%) | Compare |
| IPSC Century Therapeutics, Inc. | $273.4M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +26.66% (above 0%: growing) | 100.00% | 0.00% | |
| TTRX Turn Therapeutics Inc. | $273.0M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | Compare |
| VOGX Vogenx Inc | $270.8M | — | — | — | n/m | — | — | 0.00% | Compare |
| SABS SAB Biotherapeutics, Inc. | $267.5M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RCKT Rocket Pharmaceuticals, Inc. | $267.3M | — (loss-making) | — | — | n/m | +19.16% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $273.4M | — | — | +13,515.00% | — | −22.15% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
2.40%
TCG Crossover Management, LLC Entities
9.97%
RA Capital Healthcare Fund, L.P.
9.97%
Deep Track Capital, LP Entities
7.49%
Bayer World Investments B.V.
7.04%
Venrock Healthcare Capital Partners EG, L.P. Entities
7.01%
Commodore Capital LP
7.01%
RTW Investments, LP Entities
7.01%
Versant Entities
6.76%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement